SMA Research Platform

Slide-seqV2 and MERFISH mapping drug penetration zones and resistant niches in SMA spinal cord tissue.

Wyss Institute microphysiological systems modeling neuromuscular junction, EV drug delivery, and retrograde muscle→nerve signaling.

Michael Levin's Vmem manipulation and electroceuticals for activating endogenous regeneration in motor neurons.

dCas9/CRISPRi silencing disease-causing genes without DNA cuts, modeled on FSHD/DUX4 approach for SMN2 upregulation.

Hibernating bears preserve muscle mass through SUMOylation and protein homeostasis — mechanisms potentially applicable to SMA.

Cell dormancy and quiescence as neuroprotection strategy, inspired by zebrafish survivorship and NDRG1 stress response.

Lee Rubin (Harvard) — liver/metabolic involvement in SMA suggests combination therapy targeting both neuronal and systemic pathways.

Targeting extracellular matrix remodeling and fibrosis in SMA muscle, including SULF1/CD44 pathway connections.

Axolotl and zebrafish splicing programs for regeneration — identifying silenced regeneration genes in human SMA motor neurons.

Designing compounds that modify SMN2 splicing AND influence ion channels or anti-fibrotic pathways simultaneously.

Sequestering hnRNP A1 via RNA decoys to prevent SMN2 exon 7 skipping — inspired by splicing factor competition models.

Bioenergetic rescue via PGC-1alpha activation and NAD+ supplementation to compensate for SMN-dependent metabolic deficits.

Reverse PROTACs: targeted deubiquitination to stabilize SMN protein and prevent degradation.

Mechanical stimulation activating HSP chaperones for neuroprotection — whole body vibration as adjunct SMA therapy.

Gut-brain axis modulation via engineered probiotics producing butyrate/HDAC inhibitors for systemic SMN upregulation.

Epidural spinal cord stimulation targeting proprioceptive circuits to reactivate dormant motor neurons — Capogrosso (Pittsburgh) / Simon (Leipzig) / ESPACE Europe. Sub-motor threshold stimulation activates Ia afferents, re-establishing proprioceptive-motor circuit. Pilot results show 'spectacular' motor improvement after 1 month of 2h/day stimulation.

SMA is increasingly recognized as a circuit disease, not just motor neuron death. Mentis lab (Columbia) showed Ia afferent synapse loss on motor neurons precedes motor neuron degeneration. DRG neuron dysfunction, disrupted sensory-motor connectivity, and proprioceptive innervation specificity loss contribute to motor circuit failure. Motor neuron counting varies 0-80% across labs — methodology problems confound disease understanding. Therapeutic window may be larger than thought if circuit rescue happens before cell death.

SMN directly interacts with Profilin 1 (PFN1) in motor neurons (PMID 26401655). Pathway: SMN→PFN1→RhoA→ROCK→LIMK→CFL2→actin-cofilin rods→TDP-43 aggregation. ROCK1/2 elevated in SMNΔ7 mice, phospho-cofilin elevated in SMA models + patient fibroblasts. Fasudil (ROCK inhibitor, approved in Japan/China for stroke) crosses BBB, Phase 2 in ALS (NCT03792490). Nobody has tested ROCK inhibitors in SMA — first-in-field opportunity. MDI-117740 (LIMK inhibitor, published 2025) is more specific alternative.

Do SMA patients on therapy face accelerated cellular aging? Chronic SMN deficiency may activate senescence pathways (p16/p21), SASP, and mitochondrial dysfunction — all hallmarks of aging. Senolytics (dasatinib + quercetin) could reduce senescent cell burden. The mTOR pathway is dysregulated in SMA and is a central aging regulator. As more SMA patients survive into adulthood, understanding long-term cellular effects becomes critical.

Beyond HDAC inhibitors: permanently alter SMN2 expression via targeted epigenetic editing. dCas9-p300 could activate the SMN2 promoter without DNA cuts. DNA methylation at the SMN2 locus may suppress expression — DNMT inhibitors could reverse this. EZH2 (H3K27me3) and DOT1L (H3K79me2) may regulate SMN2 chromatin state. Non-coding RNAs (lncRNAs, circRNAs) provide additional regulatory layers.

The gut microbiome influences neuroinflammation and neurotrophic factor production. SMA is increasingly recognized as a multisystem disease affecting GI tract. Butyrate (microbial metabolite) is a natural HDAC inhibitor that could increase SMN levels. Engineered probiotics could deliver SMN-enhancing compounds locally. SMA mouse models show GI dysfunction — is the microbiome altered?

Necroptosis (RIPK1/RIPK3/MLKL pathway) is activated in SMA motor neurons, Schwann cells, and skeletal muscle. Martinez-Espana (SMA Europe 2026) showed 4-AP prevents motoneuron deafferentation via necroptotic mechanisms. SARM1 (axon degeneration master regulator) may cooperate with necroptosis. Necrostatin-1 shows mixed results in SMA mice. RIPK1 inhibitors in Phase 2 for Alzheimer's. SARM1 inhibitors in trials for neuropathy. Combination of necroptosis inhibitor + SMN therapy could address downstream damage.